PUMA BIOTECHNOLOGY, INC.

Company

GOLDMAN SACHS GROUP INC

Filed

February 8, 2022

Accession Number

0000769993-22-000139

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →